Zai Lab Starts Phase 3 Trial of ZL-2306 as First-Line Maintenance Therapy for Ovarian Cancer

Zai Lab Starts Phase 3 Trial of ZL-2306 as First-Line Maintenance Therapy for Ovarian Cancer
A Phase 3 clinical trial testing the investigational medication ZL-2306 (niraparib) as a maintenance therapy for ovarian cancer patients who are responding to their first-line chemotherapy has dosed its first participant, Zai Lab announced. Niraparib is already available in the U.S. and EU under the brand name Zejula (by Tesaro) for the maintenance of ovarian cancer patients

Knowledge is power when living with ovarian cancer.

Get access to the web’s leading Ovarian Cancer news & insights for as little as 16¢/day.
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *